NovaBridge Secures FDA Confirmation for Accelerated Approval Potential of Givastomig
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy NBP?
Source: Newsfilter
- FDA Approval Pathway Confirmation: NovaBridge's meeting with the FDA confirmed the potential for accelerated approval of givastomig in 1L Her2-, CLDN 18.2+, PD-L1+ gastric cancer patients, marking a significant milestone in the company's innovative drug development.
- Registration Trial Plans: The company plans to initiate a registrational Phase 3 trial in Q4 2026, combining immunochemotherapy with a primary endpoint of objective response rate (ORR), which will provide critical data support for accelerated approval.
- Clinical Trial Results: In the Phase 1b trial, givastomig demonstrated a 75% ORR, showing good responses across varying PD-L1 and CLDN 18.2 expression levels, indicating its potential in gastric cancer treatment.
- Broad Market Prospects: As the first bispecific antibody targeting CLDN 18.2, givastomig is poised to become a best-in-class option for gastric cancer treatment, further solidifying NovaBridge's market position in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBP
Wall Street analysts forecast NBP stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.460
Low
7.00
Averages
8.00
High
9.00
Current: 2.460
Low
7.00
Averages
8.00
High
9.00
About NBP
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NovaBridge Secures FDA Confirmation for Accelerated Approval Potential of Givastomig
- FDA Approval Pathway Confirmation: NovaBridge's meeting with the FDA confirmed the potential for accelerated approval of givastomig in 1L Her2-, CLDN 18.2+, PD-L1+ gastric cancer patients, marking a significant milestone in the company's innovative drug development.
- Registration Trial Plans: The company plans to initiate a registrational Phase 3 trial in Q4 2026, combining immunochemotherapy with a primary endpoint of objective response rate (ORR), which will provide critical data support for accelerated approval.
- Clinical Trial Results: In the Phase 1b trial, givastomig demonstrated a 75% ORR, showing good responses across varying PD-L1 and CLDN 18.2 expression levels, indicating its potential in gastric cancer treatment.
- Broad Market Prospects: As the first bispecific antibody targeting CLDN 18.2, givastomig is poised to become a best-in-class option for gastric cancer treatment, further solidifying NovaBridge's market position in the biopharmaceutical sector.
See More
NovaBridge Biosciences Reports Positive Phase 2a Results for VIS-101
- Clinical Trial Results: NovaBridge Biosciences' VIS-101 demonstrated significant efficacy in the Phase 2a trial for wet age-related macular degeneration (AMD), with both 3 mg and 6 mg cohorts showing improvements of over 10 ETDRS letters in Best Corrected Visual Acuity (BVCA) and reductions in central subfield thickness (CST) by 100-150 mm, indicating strong therapeutic potential.
- Patient Safety: The study enrolled 38 patients in China, revealing a favorable safety profile for VIS-101 with no dose-limiting toxicity, which positions the drug as a potential best-in-class treatment option and enhances market confidence in its prospects.
- Future Research Plans: The company plans to initiate a dose-determining Phase 2b study in the second half of 2026, followed by a global Phase 3 program in 2027, which will support the market introduction and clinical application of VIS-101, potentially driving future growth for the company.
- Market Performance Analysis: Despite a 23.08% decline in NovaBridge Biosciences' stock over the past 12 months, the current stock price is 14.2% above its 20-day simple moving average (SMA), indicating short-term strength; combined with a neutral RSI and bullish MACD, this suggests optimistic market sentiment regarding the company's future outlook.
See More
Ooma Inc Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Ooma Inc reported Q4 earnings of $0.34 per share, surpassing analyst expectations of $0.30, indicating strong profitability growth and boosting market confidence in its future performance.
- Sales Growth: The company achieved quarterly sales of $74.584 million, exceeding the analyst consensus of $72.549 million, reflecting Ooma's solid performance in market demand and product sales, which helps increase its market share.
- Stock Surge: Ooma's shares jumped 11.3% to $14.46 during Thursday's session, reflecting a positive investor reaction to the company's financial performance, potentially attracting more investor interest.
- Optimistic Outlook: Ooma issued FY27 adjusted EPS guidance above market expectations, further enhancing investor confidence in the company's long-term growth potential.
See More
NovaBridge Announces VIS-101 Clinical Data Update
- Clinical Trial Progress: NovaBridge is conducting a randomized dose-ranging Phase 2a study for VIS-101, aimed at providing more effective treatment for patients with wet age-related macular degeneration (AMD), which is expected to significantly enhance patient quality of life.
- Global Rights Control: Visara, as a majority-owned subsidiary of NovaBridge, holds global development and commercialization rights to VIS-101 outside Greater China and certain Asian territories, which will strongly support the company's expansion in international markets.
- Virtual Update Meeting: NovaBridge plans to host a virtual business update call on March 9, 2026, to review clinical data for VIS-101, aiming to bolster investor confidence in the company's R&D progress.
- Innovative Drug Development: VIS-101, as a dual VEGF-A/ANG-2 inhibitor, has the potential to become the best-in-class treatment for wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO), potentially transforming the current standard of care.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives on their future performance, which could influence investor decisions and market sentiment.
- AMZN Stock Outlook: Analysts' opinions on Amazon (AMZN) stock indicate mixed views on its future growth potential, prompting investors to pay close attention to the latest ratings and recommendations when considering purchases.
- Impact of Rating Changes: Upgrades and downgrades from analysts can lead to stock price volatility, necessitating that investors closely monitor these changes to timely adjust their investment strategies and optimize their portfolios.
- Market Sentiment Reflection: Changes in analyst ratings not only affect individual stock performance but can also impact overall market sentiment, urging investors to consider these factors comprehensively for informed investment decisions.
See More
NovaBridge Biosciences' Chairman Plans to Buy $5 Million in ADSs
- Chairman's Purchase Plan: Fu Wei, Executive Chairman of NovaBridge Biosciences, intends to purchase up to $5 million in the company's ADSs through his controlled entity in open market transactions, reflecting confidence in the company's future growth.
- Positive Clinical Data: The recent positive dose expansion data for givastomig from the Phase 1b study reinforces NovaBridge's clinical development capabilities and market potential in treating gastric cancer.
- Global Platform Development: NovaBridge is committed to accelerating access to innovative medicines by combining deep business development expertise with agile clinical development, showcasing the strategic value of its global biotechnology platform.
- Diverse Pipeline: The company's pipeline includes potential best-in-class therapies like givastomig and VIS-101, targeting gastric cancer and other malignancies, demonstrating its diversity and innovation in the biopharmaceutical sector.
See More
NovaBridge Secures FDA Confirmation for Accelerated Approval Potential of Givastomig
- FDA Approval Pathway Confirmation: NovaBridge's meeting with the FDA confirmed the potential for accelerated approval of givastomig in 1L Her2-, CLDN 18.2+, PD-L1+ gastric cancer patients, marking a significant milestone in the company's innovative drug development.
- Registration Trial Plans: The company plans to initiate a registrational Phase 3 trial in Q4 2026, combining immunochemotherapy with a primary endpoint of objective response rate (ORR), which will provide critical data support for accelerated approval.
- Clinical Trial Results: In the Phase 1b trial, givastomig demonstrated a 75% ORR, showing good responses across varying PD-L1 and CLDN 18.2 expression levels, indicating its potential in gastric cancer treatment.
- Broad Market Prospects: As the first bispecific antibody targeting CLDN 18.2, givastomig is poised to become a best-in-class option for gastric cancer treatment, further solidifying NovaBridge's market position in the biopharmaceutical sector.
See More
NovaBridge Biosciences Reports Positive Phase 2a Results for VIS-101
- Clinical Trial Results: NovaBridge Biosciences' VIS-101 demonstrated significant efficacy in the Phase 2a trial for wet age-related macular degeneration (AMD), with both 3 mg and 6 mg cohorts showing improvements of over 10 ETDRS letters in Best Corrected Visual Acuity (BVCA) and reductions in central subfield thickness (CST) by 100-150 mm, indicating strong therapeutic potential.
- Patient Safety: The study enrolled 38 patients in China, revealing a favorable safety profile for VIS-101 with no dose-limiting toxicity, which positions the drug as a potential best-in-class treatment option and enhances market confidence in its prospects.
- Future Research Plans: The company plans to initiate a dose-determining Phase 2b study in the second half of 2026, followed by a global Phase 3 program in 2027, which will support the market introduction and clinical application of VIS-101, potentially driving future growth for the company.
- Market Performance Analysis: Despite a 23.08% decline in NovaBridge Biosciences' stock over the past 12 months, the current stock price is 14.2% above its 20-day simple moving average (SMA), indicating short-term strength; combined with a neutral RSI and bullish MACD, this suggests optimistic market sentiment regarding the company's future outlook.
See More
Ooma Inc Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Ooma Inc reported Q4 earnings of $0.34 per share, surpassing analyst expectations of $0.30, indicating strong profitability growth and boosting market confidence in its future performance.
- Sales Growth: The company achieved quarterly sales of $74.584 million, exceeding the analyst consensus of $72.549 million, reflecting Ooma's solid performance in market demand and product sales, which helps increase its market share.
- Stock Surge: Ooma's shares jumped 11.3% to $14.46 during Thursday's session, reflecting a positive investor reaction to the company's financial performance, potentially attracting more investor interest.
- Optimistic Outlook: Ooma issued FY27 adjusted EPS guidance above market expectations, further enhancing investor confidence in the company's long-term growth potential.
See More
NovaBridge Announces VIS-101 Clinical Data Update
- Clinical Trial Progress: NovaBridge is conducting a randomized dose-ranging Phase 2a study for VIS-101, aimed at providing more effective treatment for patients with wet age-related macular degeneration (AMD), which is expected to significantly enhance patient quality of life.
- Global Rights Control: Visara, as a majority-owned subsidiary of NovaBridge, holds global development and commercialization rights to VIS-101 outside Greater China and certain Asian territories, which will strongly support the company's expansion in international markets.
- Virtual Update Meeting: NovaBridge plans to host a virtual business update call on March 9, 2026, to review clinical data for VIS-101, aiming to bolster investor confidence in the company's R&D progress.
- Innovative Drug Development: VIS-101, as a dual VEGF-A/ANG-2 inhibitor, has the potential to become the best-in-class treatment for wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO), potentially transforming the current standard of care.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives on their future performance, which could influence investor decisions and market sentiment.
- AMZN Stock Outlook: Analysts' opinions on Amazon (AMZN) stock indicate mixed views on its future growth potential, prompting investors to pay close attention to the latest ratings and recommendations when considering purchases.
- Impact of Rating Changes: Upgrades and downgrades from analysts can lead to stock price volatility, necessitating that investors closely monitor these changes to timely adjust their investment strategies and optimize their portfolios.
- Market Sentiment Reflection: Changes in analyst ratings not only affect individual stock performance but can also impact overall market sentiment, urging investors to consider these factors comprehensively for informed investment decisions.
See More
NovaBridge Biosciences' Chairman Plans to Buy $5 Million in ADSs
- Chairman's Purchase Plan: Fu Wei, Executive Chairman of NovaBridge Biosciences, intends to purchase up to $5 million in the company's ADSs through his controlled entity in open market transactions, reflecting confidence in the company's future growth.
- Positive Clinical Data: The recent positive dose expansion data for givastomig from the Phase 1b study reinforces NovaBridge's clinical development capabilities and market potential in treating gastric cancer.
- Global Platform Development: NovaBridge is committed to accelerating access to innovative medicines by combining deep business development expertise with agile clinical development, showcasing the strategic value of its global biotechnology platform.
- Diverse Pipeline: The company's pipeline includes potential best-in-class therapies like givastomig and VIS-101, targeting gastric cancer and other malignancies, demonstrating its diversity and innovation in the biopharmaceutical sector.
See More
